Vivek Nagaraja
@vivnag
Followers
616
Following
89
Media
26
Statuses
168
Rheumatology Division Chair, @MayoClinic Arizona | Researcher #rheumatology #MayoClin, @scleroderma, @ILD. All tweets are my own.
Phoenix, AZ
Joined September 2009
Had a great time speaking & co-hosting (with Paramvir Sidhu) #PRA #Crosstalk2024 focussed on #scleroderma & #vasculitis. Thx to all speakers @MdWarrington, @aczam, M.Pham, Meg Sullivan, Clint Jokerst, @MDSachin, Robert Scott, @AnvariEvamaria , Maggie Ryan. Thx to sponsors.
1
2
13
Pulmonary Rehabilitation has short-term benefits in CTD-ILD. See our latest article. A prospective study affected by the pandemic. Took 5-years and three journals to publish. https://t.co/44JHtLwzTR Thanks to @sclerodermaUM, @gedert_rosemary, and team
journals.sagepub.com
Background and Objectives: Interstitial lung disease (ILD) is a common manifestation of connective tissue disease (CTD). (a) Pulmonary rehabilitation (PR) can b...
0
2
8
mRSS pearls ✅assess skin thickening and NOT 🚫tethering ✅assess for normal skin involvement vs. abnormal ✅if abnormal, is it is mild, moderate or severe over the anatomical area ✅give a score of 0=normal, 1=mild thickness, 2= moderate, and 3= severe @IRACON24Blr
0
11
40
A 59-year-old man initially had fevers and truncal rash; two weeks later, joint pain and bilateral hearing loss developed. What is the differential diagnosis? Read the Morning Report: https://t.co/v7hrS3I2Zr
#MedTwitter @Sarahamjad_ @vivnag @MayoClinicSOM
0
4
6
A truly unique presentation #neurosyphilis
Morning Report: “A 59-Year-Old Man with a Rash and Hearing Loss” by @Sarahamjad_, BS, @vivnag, MD, and Stella X. Chen, MD https://t.co/v7hrS3I2Zr
#ClinicalMedicine @MayoClinicSOM
0
0
1
🙌Novel auto-antibody in #SSc 👉Anti-anti-PRMT5 antibodies ✅️correlated with progression in skin and lung ✅️distinguished SSc from healthy, lupus and Sjögren’s syndrom ✅️induced SSc-like manifestations in mice https://t.co/DaTCfLe2te
0
67
136
➡️ https://t.co/AGMs354R0u 📷Testing nerandomilast (PDE4 b inh) @Boehringer and amlitelimab (anti OX 40L) @sanofi ➡️Phase 2b program ➡️ 150 sites in 25 countries
srfcure.org
CONQUEST platform clinical trial anticipates enrolling eligible patients late 2023 with the goal of development and approval of effective therapies.
0
4
11
It was great to catch up with @sclerodermaUM Dinesh Khanna - a wonderful mentor and a dear friend. Thank you for all the guidance in shaping my career. #CONQUEST @srfcure
3
1
24
🙌 Proud of this tri-site participation from @MayoClinic in ✨CONQUEST✨ 1st ever Global ‘Platform Clinical Trial’ in #Rheumatology funded by Scleroderma Research Foundation @SRFCure, that promises to accelerate drug development in #SclerodermaILD ! 👉 https://t.co/eC3PyRQcel
2
3
16
“A potential explanation for differential access to CART19 among minoritized racial groups, particularly in highly resourced academic centers, is racial disparity in treatment recommendations.” Read the full editorial: https://t.co/sIa3IPrIye
0
6
14
📣75th anniversary of cortisone discovery. 💊 This #wonderdrug is the legacy of #Mayoclinicrheumatology 📝a masterful article by #RheumGiants #DrMatteson and #DrHunder
@JohnDavisIII @MdWarrington @AshimaMakol
Grear review of Philip S Hench and the discovery of cortisone - by Drs Matteson and Hunder in Ann Rheum Dis https://t.co/EoYtDYsk4K
0
5
19
Delighted to share our comprehensive review on diagnostic approaches to #CTD-ILD (#SARD-ILD). An update for clinicians Thx to @MayoClinic co-authors: @aczam , Lewis Wesselius, Michael Gotway, @htazmd, and Alejandro Diaz https://t.co/jIjRvzc5e2
0
0
7
Our latest review on what role the imaging innovations may play in the future in CTD-ILDs (aka SARD-ILD). Thanks to @MayoClinic & @UAzPACCS team Clint Jokerst, @MDSachin Ana Zamora, and Kavitha Yaddanapudi. It is an open access article.
emjreviews.com
Interstitial lung disease (ILD) is a relatively frequent manifestation of systemic autoimmune rheumatic disorders (SARD)...
1
3
8
Systemic sclerosis with morphea-like plaques histopathologically mimic... https://t.co/yCxuhobZxG A unique case of systemic sclerosis with co-existent morphea like plaques and surprising histopathology. Thanks to Ana Aragon-Sierra, David DiCaudo, and Aaron Mangold @MayoClinic
0
0
5
One more day to go. It is sure to be an informative session. Don’t forget to register even for asynchronous viewing of this webinar.
1
0
0
7th session @MayoClinic #Telehealth in #Rheumatology webinar Digital Technologies to Support Clinical Care and Real-World Data Generation By Jeffrey R Curtis, MD MS MPH @RADoctor February 21, 2024, 11:30 a.m.-12:30 p.m. CT Free Registration https://t.co/wYRbAuJF2F
1
2
5
7th session @MayoClinic #Telehealth in #Rheumatology webinar Digital Technologies to Support Clinical Care and Real-World Data Generation By Jeffrey R Curtis, MD MS MPH @RADoctor February 21, 2024, 11:30 a.m.-12:30 p.m. CT Free Registration https://t.co/wYRbAuJF2F
1
2
5
The inaugural @MayoClinic #DigitalHealth Research Symposium will occur on 3/20/24 from 12-2pm CDT. This free virtual event will feature panel discussions & presentations about how digital solutions are transforming healthcare. Reserve your seat here ➡️
0
2
6
With Molecular profiling, 2 FDA approved Tx & 💪pipeline of Novel 💊we’ve come a LONG way.. Excited & Honored to moderate this years Philip S. Hench,MD,Memorial Lecture @ACRheum! ✨#SCLERODERMA 2022:Moving to Precision Management✨by Dr. Fredrick Wigley #ACR22 #ACRambassador
0
6
18
4-days to go! 6th session @MayoClinic #Telehealth in #Rheumatology webinar Empowering Scleroderma Patients through Digital Health Interventions. By Dr. Susan Murphy, ScD, OTR @UMich December 14, 2023 11:30 AM CT Free Registration https://t.co/RnuzUecCFT
0
1
8